Targeting aldehyde dehydrogenase for prostate cancer therapies

Targeting aldehyde dehydrogenase for prostate cancer therapies

Prostate cancer (PCa) is the most common cancer in men in the United States. About 10 – 20% of PCa progress to castration-resistant PCa (CRPC), which is accompanied by metastasis and therapeutic resistance. Aldehyde dehydrogenase (ALDH) is famous as a marker of cancer stem-like cells in different ca...

Full description

Bibliographic Details
Main Authors: Miao Ma, Wenyou He, Keyu Zhao, Linyuan Xue, Siyuan Xia, Baotong Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
prostate cancer
aldehyde dehydrogenase
targeted therapy
drug resistance
cancer stem-like cells (CSCs)
signaling transduction
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1006340/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1006340/full

Similar Items